Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Shares Outstanding (Weighted Average) (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Shares Outstanding (Weighted Average) data on record, last reported at $14.2 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 435.9% year-over-year to $14.2 million; the TTM value through Sep 2025 reached $14.2 million, up 435.9%, while the annual FY2024 figure was $2.5 million, 39.21% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $14.2 million in Q3 2025 per BTAI's latest filing, up from $6.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $29.3 million in Q3 2023 and bottomed at $1.8 million in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 4 years is $15.7 million, with a median of $14.2 million recorded in 2025.
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 93.5% in 2023, then soared 435.9% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $28.0 million in 2022, then plummeted by 93.5% to $1.8 million in 2023, then soared by 39.21% to $2.5 million in 2024, then soared by 460.0% to $14.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $14.2 million in Q3 2025, $6.3 million in Q2 2025, and $4.8 million in Q1 2025.